{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000054","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.919463+00:00","generated_at":"2026-05-31T23:47:12.422689+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"vTv Therapeutics expands Newsoara license globally for $20M upfront, up to $96M milestones","bullets":["Second Amendment to License Agreement with Newsoara Biopharma expands original China license to global.","Newsoara to pay $20M upfront within one year; if not paid, amendment void.","Up to $41M in development milestones and $35M in sales milestones, plus mid-to-upper single-digit royalties.","vTv Therapeutics LLC (subsidiary of vTv Therapeutics Inc.) is the licensor."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000054","json":"https://secwatch.observer/filing/0001641489-24-000054.json","markdown":"https://secwatch.observer/filing/0001641489-24-000054.md","text":"https://secwatch.observer/filing/0001641489-24-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000054/0001641489-24-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000054/vtvt-20240626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:47:12.422689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}